Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3001
Cytokinetics
CYTK
$8.75B
| $336K | ﹤0.01% |
10,167
-110,500
| -92% | -$3.84M |
2023 Q4
6 quarters
|
|
3002
AMC Global Media
AMCX
$446M
| $335K | ﹤0.01% |
+53,500
| New | +$338K |
2025 Q2
0 quarters
|
|
3003
Tango Therapeutics
TNGX
$4.01B
| $335K | ﹤0.01% |
65,500
-109,000
| -62% | -$270K |
2024 Q4
2 quarters
|
|
3004
Dream Finders Homes
DFH
$849M
| $334K | ﹤0.01% |
13,300
-96,310
| -88% | -$2.16M |
2022 Q4
10 quarters
|
|
3005
IRIDEX
IRIX
$15.6M
| $334K | ﹤0.01% |
378,760
-400
| -0.1% | -$407 |
2013 Q2
48 quarters
|
|
3006
Quest Resource Holding
QRHC
$29.1M
| $333K | ﹤0.01% |
165,092
-16,900
| -9% | -$38.8K |
2015 Q3
39 quarters
|
|
3007
Ostin Technology Group
OST
| $333K | ﹤0.01% |
+84,192
| New | +$8.51M |
2025 Q2
0 quarters
|
|
|
AIFC
3008
AI Financial Corp
AIFC
$61M
| $333K | ﹤0.01% |
45,900
-46,267
| -50% | -$325K |
2024 Q4
2 quarters
|
|
3009
RenovoRx
RNXT
$57.8M
| $331K | ﹤0.01% |
251,800
+224,144
| +810% | +$255K |
2024 Q4
2 quarters
|
|
3010
i3 Verticals
IIIV
$288M
| $330K | ﹤0.01% |
12,000
-8,300
| -41% | -$208K |
2022 Q4
10 quarters
|
|
|
UHG
3011
DELISTED
United Homes Group
UHG
| $329K | ﹤0.01% |
+113,500
| New | +$295K |
2025 Q2
0 quarters
|
|
3012
WisdomTree India Earnings Fund ETF
EPI
$1.78B
| $328K | ﹤0.01% |
+6,900
| New | +$313K |
2025 Q2
0 quarters
|
|
|
OTLY
3013
Oatly Group
OTLY
$338M
| $327K | ﹤0.01% |
27,549
-3,129
| -10% | -$33K |
2023 Q3
7 quarters
|
|
|
LITS
3014
Lite Strategy Inc
LITS
$38.6M
| $327K | ﹤0.01% |
132,346
-2,100
| -2% | -$4.49K |
2015 Q3
39 quarters
|
|
|
CWAN
3015
DELISTED
Clearwater Analytics
CWAN
| $327K | ﹤0.01% |
14,899
-1,344,201
| -99% | -$30.9M |
2022 Q1
13 quarters
|
|
|
FWDI
3016
Forward Industries Inc
FWDI
$560M
| $325K | ﹤0.01% |
55,593
+3,901
| +8% | +$25.1K |
2013 Q2
48 quarters
|
|
3017
Oramed Pharmaceuticals
ORMP
$180M
| $324K | ﹤0.01% |
144,200
+1,700
| +1% | +$3.75K |
2023 Q1
9 quarters
|
|
|
NEWP
3018
New Pacific Metals
NEWP
$1.22B
| $323K | ﹤0.01% |
241,314
-91,511
| -27% | -$116K |
2024 Q1
5 quarters
|
|
3019
Nuvectis Pharma
NVCT
$689M
| $321K | ﹤0.01% |
+43,000
| New | +$390K |
2025 Q2
0 quarters
|
|
3020
MDxHealth
MDXH
$56.3M
| $321K | ﹤0.01% |
145,273
+23,073
| +19% | +$43.3K |
2024 Q3
3 quarters
|
|
|
AHT
3021
Ashford Hospitality Trust
AHT
$14M
| $320K | ﹤0.01% |
53,103
+1,100
| +2% | +$6.67K |
2022 Q1
13 quarters
|
|
3022
NeuroOne Medical Technologies
NMTC
$10.2M
| $318K | ﹤0.01% |
+78,150
| New | +$289K |
2025 Q2
0 quarters
|
|
|
DFAI
3023
Dimensional International Core Equity Market ETF
DFAI
$17.8B
| $318K | ﹤0.01% |
+9,200
| New | +$301K |
2025 Q2
0 quarters
|
|
3024
Traeger
COOK
$144M
| $318K | ﹤0.01% |
3,718
+646
| +21% | +$49.6K |
2024 Q2
4 quarters
|
|
3025
iShares 20+ Year Treasury Bond ETF
TLT
$46.7B
| $318K | ﹤0.01% |
3,600
-89,686
| -96% | -$7.82M |
2024 Q3
3 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.